

Date: May 08, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation of Board Meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of Board of Directors of the Company will be held on Wednesday, May 15, 2024, inter-alia to consider and approve the standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31, 2024.

Further to the above, please note that the Board at its said meeting will also consider and evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals.

Further, in continuation of our earlier letter dated March 27, 2024 under subject 'Closure of Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's 'Code of Conduct for Prevention of Insider Trading', the trading window for trading in the securities of the Company shall remain closed till May 17, 2024.

The above notice and details are also being uploaded on the website of the Company at www.mankindpharma.com.

You are requested to kindly take the same on records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Pradeep Chugh
Company Secretary and Compliance Officer